UK Medicines Information for NHS professionals ... Trade Name: Qnexa : Entry Type: New formulation : Developmental Status: UK: Pre-registration (Filed)

Diet drugs may have side effects, and while drugs cannot take the place of diet and exercise, drugs like phentermine and topiramate do aid with weight loss study finds.

Updated– The experimental diet drug combination of phentermine and topiramate demonstrated “robust efficacy” in CONQUER, a large new trial published online in the Lancet.

1 Answer - Posted in: migraine, phentermine, topiramate, weight loss - Answer: Checked on the Interactions Checker, no interactions between ...

Qnexa (phentermine and topiramate) is a new drug in development for the treatment of obesity. Qnexa information includes news, clinical trial results and side effects.

... cluster headache migraine headache, cocaine dependence, and Borderline Personality Disorder. Topiramate is also being studied with a mixture of phentermine to form a drug called Qnexa ...

Testimony on Phentermine and Topiramate (Qnexa) July 15, 2010. Testimony before FDA's Endocrinologic and Metabolic Drugs Advisory Committee Sidney Wolfe, M.D. Charles Preston ...

On July 15, 2010, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted against FDA approval of Vivus’ Qnexa (phentermine/topiramate), with six votes in favor ...

A drug called Qnexa, which is really just a combination of phentermine and Topamax (topiramate), caused half of the patients to lose an average of 25.1 pounds after six months ...

Seventy percent of subjects who took a high dose of the two drugs, phentermine and topiramate, experienced a 5 percent weight loss after one year.

RCT: Low-dose, controlled-release, phentermine plus topiramate in overweight and obese ... treatment and remains the most widely prescribed anti-obesity drug in the US. Topiramate ...

The study used once-daily oral doses of the combined drugs. Phentermine 7.5mg plus topiramate CR 46mg achieved 7.8 percent weight loss (p<0.0001 vs placebo).

Endocrinologic and Metabolic Drugs Advisory Committee Meeting February 22, 2012 VIVUS, Inc. QNEXA ® (Phentermine / Topiramate) Extended Release Capsules

GAITHERSBURG, Md. -- An FDA advisory panel was divided over whether to recommend approval of the investigational weight-loss drug phentermine/topiramate (Qnexa). The ...

The committee voted 20 to 2 to approve the drug. Qnexa -- a combination of the appetite suppressant phentermine and the seizure and migraine drug topiramate -- was ...

1 Endocrinologic and Metabolic Drugs Advisory Committee Meeting Silver Spring, Maryland February 22, 2012 QNEXA (Phentermine/Topiramate) NDA 22580